On October 18, 1971, President Richard Nixon emerged from the U.S. Army Post Headquarters at Fort Detrick into the sunlight of one of Frederick’s signature autumn mornings. Nearby, a crowd of dignitaries, Army officers, and journalists from local and national news outlets had gathered to hear his remarks about the former biowarfare research facility. He greeted them, paused to make a good-natured joke about the Baltimore Orioles, then delivered an announcement that altered the course of biomedical research in the United States.

Ira Pastan, Ph.D., says the FDA’s recent approval of moxetumomab pasudotox, a drug that originated in his lab, wasn’t like “hitting a home run with the bases loaded, all of it happening in 20 seconds.” In fact, it was more like 20 years.

Editor's note: Ron Defelice, a 42-year employee of the National Cancer Institute at Frederick and the facility's first Contracting Officer, passed away on December 21, 2018. You can read his obituary here. For the Poster, we’ve chosen to remember his invaluable contribution to the cancer research community.

The first open house event for the Office of Scientific Operations’ (OSO) Educational Outreach Program (EOP), held at the Advanced Technology Research Facility (ATRF), was a success according to program coordinator Cathy Cullen. “We had more volunteers sign up in person than in response to the emails, and it was a lot more fun, too.”

During an address to the recent annual meeting of the American Society of Clinical Oncology, NCI Director Norman “Ned” Sharpless, M.D., announced that the National Cancer Institute is committing $10 million to support NCI-run clinical trials this year. The funds, which will be given in addition to the normal budget, are dedicated to trials conducted within the NCI Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program.